title: Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane.
abstract: The influence of concomitant administration of bovine lactoferrin (bLF) on induction of aberrant crypt foci (ACF) by azoxymethane was investigated in male F344 rats. Two percent bLF and 3% Bifidobacterium longum (B. longum), as a positive control, significantly decreased the numbers of ACF as well as the total numbers of aberrant crypts reproducibly in three independent studies (2% bLF, P < 0.01; 3% B. longum, P < 0.05). Most importantly large size foci composed of four or more crypts were always significantly decreased by 2% bLF (P < 0.05). Additional investigation of the natural killer activity of spleen cells demonstrated enhancement by bLF (P < 0.01) and B. longum (P < 0.01) in line with the levels of influence on foci induction, indicating a possible role for elevated immune cytotoxicity in the observed inhibition.
authors.affiliation: Chemotherapy Division, National Cancer Center Research Institute, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sekine
authors.forename: Y
authors.initials: Y
authors.lastname: Ushida
authors.forename: T
authors.initials: T
authors.lastname: Kuhara
authors.forename: M
authors.initials: M
authors.lastname: Iigo
authors.forename: H
authors.initials: H
authors.lastname: Baba-Toriyama
authors.forename: M A
authors.initials: MA
authors.lastname: Moore
authors.forename: M
authors.initials: M
authors.lastname: Murakoshi
authors.forename: Y
authors.initials: Y
authors.lastname: Satomi
authors.forename: H
authors.initials: H
authors.lastname: Nishino
authors.forename: T
authors.initials: T
authors.lastname: Kakizoe
authors.forename: H
authors.initials: H
authors.lastname: Tsuda
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001397:Azoxymethane / Q000633:toxicity*; D001644:Bifidobacterium / Q000502:physiology; D002273:Carcinogens / Q000633:toxicity*; D018890:Chemoprevention; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D004334:Drug Administration Schedule; D007694:Killer Cells, Natural / Q000276:immunology*; D007781:Lactoferrin / Q000627:therapeutic use*; D008297:Male; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D016588:Anticarcinogenic Agents; D002273:Carcinogens; D007781:Lactoferrin; D001397:Azoxymethane